{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hobson CA"],"funding":["ARC (association recherche contre le cancer) foundation","Fondation pour la Recherche Médicale"],"pagination":["e0044722"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9487638"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["66(9)"],"pubmed_abstract":["First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam. After the marketing of ceftazidime-avibactam, numerous variants of KPC resistant to this association have been described among isolates recovered from clinical samples or derived from experimental studies. In KPC variants resistant to ceftazidime-avibactam, point mutations, insertions and/or deletions have been described in various hot spots. Deciphering the impact of these mutations is crucial, not only from a therapeutic point of view, but also t"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview."],"pmcid":["PMC9487638"],"funding_grant_id":["EQU201903007848","DOC20190509066"],"pubmed_authors":["Birgy A","Jacquier H","Pierrat G","Jaouen E","Hobson CA","Bonacorsi S","Bercot B","Tenaillon O"],"additional_accession":[]},"is_claimable":false,"name":"Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.","description":"First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates. These beta-lactamases conferred resistance to most beta-lactams including carbapenems but remained susceptible to new beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam. After the marketing of ceftazidime-avibactam, numerous variants of KPC resistant to this association have been described among isolates recovered from clinical samples or derived from experimental studies. In KPC variants resistant to ceftazidime-avibactam, point mutations, insertions and/or deletions have been described in various hot spots. Deciphering the impact of these mutations is crucial, not only from a therapeutic point of view, but also t","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-06-13T06:11:35.789Z","creation":"2025-04-05T23:29:31.664Z"},"accession":"S-EPMC9487638","cross_references":{"pubmed":["35980232"],"doi":["10.1128/aac.00447-22"]}}